ABSTRACT
INTRODUCTION
Cancer immunotherapy has introduced a novel class of drugs known as immune checkpoint inhibiblocking negative regulators (checkpoints) of T cell
The first agent was approved in 2011 and since then a few of them have been evaluated in clinical trials for the management of advanced neoplasias, such as metastatic melanoma, non-small cell lung cancer, advanced renal cell carcinoma, head and neck cancer [1] [2] [3] [4] [5] However, because of their mechanism of action these agents can lead to a variety of inflammatory toxicities and autoimmune consequences that can affect the gastrointestinal tract, skin, liver and endocrine system and are hence deThe endocrine immune-related adverse events include hypophysitis, primary thyroid dysfunction, adrenalitis and type 1 diabetes mellitus which present with variable degrees of severity [6] [7] [8] [9] [10] [11] 38 (Table 2) and incidence rates 47 
PATHOGENIC MECHANISMS
Tumour antigens are presented by dendritic cells T cell-mediated inhibitory signalling pathways permit tolerance to tumour anantibodies against cytotoxic T-lymphocyte antigen 4 (CTLA4), programmed cell death 1 (PD1) and programmed cell death 1 ligand 1 (PDL1) have been available data refer to ipilimumab and tremelimumab, both CTLA4-abs, nivolumab, pembrolizumab and pidilizumab, all anti-PD1 abs and atezolizumab an
Anti-CTLA4
CD28 on the T cell surface binds to the B7 co-stimulatory ligand on antigen-presenting cells to prime and activate the T cell so as to destroy the cancer higher affinity to B7 and can compete with CD28 to prevent B7 binding and enable upregulation of T cell activity, activation of mitogen-activated protein kinase which results in the for mation of activator protein 1 (AP1) complex and induction of IL-2 cytokines which [13] [14] [15] Anti-PD1 and anti-PDL1
The PD1 (programmed cell death -1) receptor (also known as CD279) is expressed on the surface of The National Cancer Institute has recommended that adverse events on patients with cancer chemotherapy be graded as per the Com- 
GENERAL MANAGEMENT OF IMMUNE-RELATED ADVERSE EVENTS
In general, treatment of moderate or severe IRAEs requires interruption of the checkpoint inhibitor and the use of corticosteroid or alternative immunosup-18 For grade 2 (moderate) immune-mediated toxicities, treatment with the checkpoint inhibitor should be withheld and not resumed until sympFor patients experiencing grade 3 or 4 (severe or lifethreatening) immune-mediated toxicities, treatment with the checkpoint inhibitor should be permanently discontinued and high doses of corticosteroids (predWhen symptoms subside to grade 1 or less, steroids 18 If symptoms do not clearly improve, particularly after approximately three days with intravenous steroids, infliximab (5mg/kg) could be administered rather than continuing with a prolonged course of high-dose 18 The need for immunosuppressive therapy to manage IRAEs does not appear to affect the response to checkpoint inhibition with either 19 The specific approach to each endocrine IRAE
ENDOCRINE SEQUELAE

Hypophysitis
Hypophysitis is a rare inflammatory condition of the pituitary gland with an incidence of 1:1,000,000 developed hypophysitis, while this consequence oc- In contrast, in another meta-analysis of PD1 inhibitors studies the risk of hypophysitis in patients treated with these agents was not significantly elevated com-
22
The authors assumed that this discrepancy could be due to the fact that Abdel-Rahman et al analyzed mainly anti-CTLA4 inhibitors studies (five RCTs evaluating ipilimumab, one evaluating tremelimumab, three for nivolumab and one for pembrolizumab), while all ten RCTs included in their analysis were for PD-1 inhibi- In a meta-analysis of PD-1 inhibi tors studies the risk of hyperthyroidism was significantly increased comwhile the risk of hypothyroidism, although elevated, 22 The combination of nivolumab/ipilimumab increased the risk of all-grade hyperthyroid ism (RR: The onset of thyroid disease usually occurs after -immunity has been reported; [33] [34] [35] however, whether individual genetic susceptibility plays a role has not -ery of pembrolizumab-induced thyroiditis in 4/7 33 It is noteworthy that two cases with hyperthyroidism who required high-dose systemic corticosteroids for the management of other immune- 31 The authors assumed that immunosuppressive therapy may prevent the development of hypothyroidism in those situation in ipilimumab-induced hypophysitis, where high dose steroids have not been shown to reverse The proposed mechanism for the development of T1DM is that lower PD-1 expressing CD4+ cells may lead to activation of autoreactive T cells that can infiltrate pancreatic islet cells and ultimately lead 41 It is suspected that high-risk HLA class -mended that clinicians managing patients undergoing anti-PD1 or anti-PDL1 therapy should carefully monitor patients for elevated levels of blood sugar, while antibodies against islet cell (ICA) and glutamic acid decarboxylase (GAD) and C-peptide should be measured in order to distinguish between T1DM and
CONCLUDING REMARKS
ICIs targeting CTLA-4 and PD-1/PDL-1 have dramatically changed the outcome of patients with use is associated with unique IRAEs (hypophysitis, thyroid disorders, adrenalitis, type 1 diabetes mellitus) which, though mostly transient and mild, can being prepared a case of primary hypoparathyroidism caused by ipilimumab and nivolumab and manifesting with acute severe symptomatic hypocalcemia was 46 Rapid identification of these IRAEs and appropriate treatment can improve It is important that patients on ICIs are informed about the potential endocrine sequelae of these treatments and especially the risk of developing cortisol Close monitoring and constant vigilance for the ocinhibitors are now achieving regulatory approval in many types of cancer, more data on conducting the long-term follow-up of these patients is urgently
LEARNING POINTS
The relative risk of hypophysitis is high in those When compared with ipilimumab, the risk of allgrade hyperthyroidism and hypothyroidism with PD-1 inhibitors monotherapy seems to be higher, while the Patients treated with a nivolumab/ipilimumab combination therapy have a significantly increased risk of all-grade hyperthyroidism and hypophysitis Adrenalitis and type 1 diabetes mellitus are rare Long-term follow-up of patients treated with T-cell checkpoint inhibitors is needed so that more data may
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